ARVN - Arvinas, Inc.
Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Arvinas, Inc. (NASDAQ: ARVN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 167,056 shares of the company's stock, valued at approximately $1,388,000. Connor
Arvinas receives a Buy rating upgrade, underpinned by Veppanu's FDA approval and a robust PROTAC platform. Despite Veppanu's approval for ESR1-mutated breast cancer, ARVN's share price remains near cash value, reflecting market skepticism about future revenues. ARVN's pipeline includes five early-stage programs and a Novartis-partnered asset, but high R&D costs and uncertain milestones temper near-term upside.
Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arvinas (NASDAQ: ARVN) said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the first approved PROTAC degrader, and an out-licensing agreement for the product with Rigel Pharmaceuticals. President and Chief Executive Officer Randy Teel said Rigel expects
Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript
Arvinas NASDAQ: ARVN said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the first approved PROTAC degrader, and an out-licensing agreement for the product with Rigel Pharmaceuticals.
Arvinas, Inc. (ARVN) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to a loss of $0.84 per share a year ago.
– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader ), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months – – Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn.
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review second quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, August 4, 2026 at 8:00 a.m. ET.
Arvinas NASDAQ: ARVN management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that may require broader development resources.
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.
NEW HAVEN, Conn. , May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Connecticut, in the Greater Boston area, and around the country, took part in the Company's fourth Arvinas Impact Day this past Friday. This company-wide day of service brings employees together to give back to their communities through volunteer activities that will make a meaningful difference across the Greater New Haven area and beyond.
Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday.
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant).
Arvinas NASDAQ: ARVN said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation.
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to earnings of $1.14 per share a year ago.
Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product on the market.
– First-ever FDA approved PROTAC supports the further development and potential of Arvinas' pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer – – Announced selection of Rigel Pharmaceuticals for the exclusive global rights to VEPPANU – – Presented ARV-102 (LRRK2 degrader) Phase 1 clinical data in patients with Parkinson's disease demonstrating reduction in endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy – – Presented ARV-6723 (HPK1 degrader) preclinical data at the American Associated of Cancer Research Annual meeting demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Initiated dosing with ARV-027 (polyQ-AR degrader) in Phase 1 healthy volunteer trial with single-ascending dose data anticipated in 2H26 – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn.